311 related articles for article (PubMed ID: 26218669)
1. Long-Term Safety of Paliperidone Extended Release in Adolescents with Schizophrenia: An Open-Label, Flexible Dose Study.
Savitz A; Lane R; Nuamah I; Singh J; Hough D; Gopal S
J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):548-57. PubMed ID: 26218669
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter Study.
Gopal S; Lane R; Nuamah I; Copenhaver M; Singh J; Hough D; Bach M; Savitz A
CNS Drugs; 2017 Sep; 31(9):797-808. PubMed ID: 28660406
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study.
Savitz AJ; Lane R; Nuamah I; Gopal S; Hough D
J Am Acad Child Adolesc Psychiatry; 2015 Feb; 54(2):126-137.e1. PubMed ID: 25617253
[TBL] [Abstract][Full Text] [Related]
4. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics.
Hargarter L; Cherubin P; Bergmans P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Schreiner A
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():1-7. PubMed ID: 25448776
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of paliperidone ER in patients with unsatisfactorily controlled schizophrenia by other antipsychotics: a flexible-dose approach.
Mauri M; Mauri MC; Adami M; Reggiardo G; Giulio C
Int Clin Psychopharmacol; 2015 Nov; 30(6):329-37. PubMed ID: 26230269
[TBL] [Abstract][Full Text] [Related]
6. A Flexible-Dose Study of Paliperidone ER in Patients With Nonacute Schizophrenia Previously Treated Unsuccessfully With Oral Olanzapine.
Kotler M; Dilbaz N; Rosa F; Paterakis P; Milanova V; Smulevich AB; Lahaye M; Schreiner A
J Psychiatr Pract; 2016 Jan; 22(1):9-21. PubMed ID: 26813484
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
Li H; Rui Q; Ning X; Xu H; Gu N
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.
Meltzer HY; Bobo WV; Nuamah IF; Lane R; Hough D; Kramer M; Eerdekens M
J Clin Psychiatry; 2008 May; 69(5):817-29. PubMed ID: 18466043
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
Tzimos A; Samokhvalov V; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460
[TBL] [Abstract][Full Text] [Related]
10. Effects of paliperidone extended release on functioning level and symptoms of patients with recent onset schizophrenia: An open-label, single-arm, flexible-dose, 12-months follow-up study.
Üçok A; Saka MC; Bilici M
Nord J Psychiatry; 2015 Aug; 69(6):426-32. PubMed ID: 25549697
[TBL] [Abstract][Full Text] [Related]
11. A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents.
Schreiner A; Bergmans P; Cherubin P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Hargarter L
Clin Ther; 2014 Oct; 36(10):1372-88.e1. PubMed ID: 25444566
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.
Davidson M; Emsley R; Kramer M; Ford L; Pan G; Lim P; Eerdekens M
Schizophr Res; 2007 Jul; 93(1-3):117-30. PubMed ID: 17466492
[TBL] [Abstract][Full Text] [Related]
13. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.
Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M; Hough D
J Psychopharmacol; 2011 May; 25(5):685-97. PubMed ID: 20615933
[TBL] [Abstract][Full Text] [Related]
14. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.
Canuso CM; Bossie CA; Amatniek J; Turkoz I; Pandina G; Cornblatt B
Early Interv Psychiatry; 2010 Feb; 4(1):64-78. PubMed ID: 20199482
[TBL] [Abstract][Full Text] [Related]
15. Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment: Post hoc analysis of an open-label, prospective study.
Si TM; Cai SL; Zhuo JM; Zhang LL
Medicine (Baltimore); 2019 Jan; 98(3):e13688. PubMed ID: 30653088
[TBL] [Abstract][Full Text] [Related]
16. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.
Schreiner A; Niehaus D; Shuriquie NA; Aadamsoo K; Korcsog P; Salinas R; Theodoropoulou P; Fernández LG; Uçok A; Tessier C; Bergmans P; Hoeben D
J Clin Psychopharmacol; 2012 Aug; 32(4):449-57. PubMed ID: 22722501
[TBL] [Abstract][Full Text] [Related]
17. Paliperidone extended release: a review of its use in the management of schizophrenia.
Chwieduk CM; Keating GM
Drugs; 2010 Jul; 70(10):1295-317. PubMed ID: 20568835
[TBL] [Abstract][Full Text] [Related]
18. Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics.
Kwon JS; Kim SN; Han J; Lee SI; Chang JS; Choi JS; Lee HJ; Cho SJ; Jun TY; Lee SH; Han C; Lee KU; Lee KK; Lee E
Int Clin Psychopharmacol; 2015 Nov; 30(6):320-8. PubMed ID: 26196188
[TBL] [Abstract][Full Text] [Related]
19. Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation.
Mauri MC; Reggiori A; Paletta S; Di Pace C; Altamura AC
Expert Opin Drug Saf; 2017 Mar; 16(3):365-379. PubMed ID: 28140680
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents.
Singh J; Robb A; Vijapurkar U; Nuamah I; Hough D
Biol Psychiatry; 2011 Dec; 70(12):1179-87. PubMed ID: 21831359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
